77 The survival rate for gallbladder cancer has shown little to no progress over the past three decades, according to a major new study that examined registry data from across the world. Researchers found that despite improved cancer treatments and increased awareness, outcomes for those diagnosed with this aggressive disease remain bleak in most regions. The findings were published in the journal Heliyon. The study, which analysed over 320,000 cases from 55 population-based cancer registry studies, reveals that the five-year relative survival rate for gallbladder cancer remains stubbornly low, fluctuating between 10 percent and 20 percent in most countries. The highest age-standardised survival rate reported was just over 30% in parts of China and South Korea, while some European countries recorded rates as low as 6 percent. Gallbladder cancer is notoriously difficult to detect early. It progresses silently, often without obvious symptoms, which results in many patients being diagnosed at a late stage. By then, treatment options are limited and the chances of long-term survival are slim. In some countries, more than 40% of patients are diagnosed after the disease has already spread to other organs. While countries in Asia have generally reported higher survival rates, the reasons for this are not entirely clear. Dietary patterns, genetic predispositions, and potentially better localised cancer monitoring could all play a role. In Korea and Japan, for instance, survival rates have gradually improved. In contrast, regions such as the US, Europe, and Brazil have seen little movement in outcomes over the same period. Economic development does not appear to guarantee better outcomes. In China, the well-developed city of Shanghai had a notably lower survival rate than less developed areas such as Zhejiang or Jiangsu. This challenges assumptions that better infrastructure or access to care directly translate into improved survival for gallbladder cancer. The survival gap across age groups is also striking. Younger patients consistently fare better, likely because they are more resilient to intensive treatment, including surgery, which remains the primary option in early-stage disease. Older individuals, who may have other health conditions, are less likely to undergo aggressive treatment, contributing to poorer outcomes. Sex-based differences in survival were not statistically significant in most countries, although incidence is generally higher among women. This may be linked to biological factors, including the effects of oestrogen on bile composition, which increases the risk of gallstone formation — a major risk factor for gallbladder cancer. Despite increasing research into immunotherapy and targeted treatments, the lack of early detection methods remains the biggest challenge. There is currently no recommended population-wide screening programme for gallbladder cancer, and tumour markers are neither reliable nor specific enough for early diagnosis. Experts agree that a breakthrough in screening is urgently needed. A test that is simple, affordable, and sensitive enough to detect gallbladder cancer in its earliest stages would likely have the biggest impact on long-term survival. Without such tools, even the most advanced treatments will offer limited benefit.